bioAffinity Technologies (NASDAQ:BIAF – Get Rating) and ICON Public (NASDAQ:ICLR – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.
Insider & Institutional Ownership
91.3% of ICON Public shares are held by institutional investors. 44.0% of ICON Public shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Get
bioAffinity Technologies alerts:
Analyst Ratings
This is a summary of current recommendations and price targets for bioAffinity Technologies and ICON Public, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| bioAffinity Technologies | 0 | 0 | 0 | 0 | N/A |
| ICON Public | 0 | 3 | 7 | 0 | 2.70 |
ICON Public has a consensus price target of $271.89, suggesting a potential upside of 47.94%. Given ICON Public's higher probable upside, analysts clearly believe ICON Public is more favorable than bioAffinity Technologies.
Profitability
This table compares bioAffinity Technologies and ICON Public's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| bioAffinity Technologies | N/A | N/A | N/A |
| ICON Public | 2.77% | 10.54% | 4.91% |
Earnings & Valuation
This table compares bioAffinity Technologies and ICON Public's revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| bioAffinity Technologies | N/A | N/A | N/A | N/A | N/A |
| ICON Public | $5.48 billion | 2.73 | $153.18 million | $2.52 | 72.93 |
ICON Public has higher revenue and earnings than bioAffinity Technologies.
Summary
ICON Public beats bioAffinity Technologies on 8 of the 8 factors compared between the two stocks.
About bioAffinity Technologies
(Get Rating)
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
About ICON Public
(Get Rating)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
